[Immunization against the ZWa (PLA1) platelet antigen: group at risk, prevention of complications. Apropos of 132 cases].
The identification of anti-ZWa (-PLA1) alloimmunisation is not very frequent. It can be observed in most perinatal alloimmune thrombocytopenias (PAT) and rare post transfusional purpuras (PTP). On the other hand, the clinical consequences of these immunisations are often dramatic, particularly for the foetuses for which there has been no prevention so far. The retrospective study of 132 cases, 123 PAT and 9 PTP, shows the possible irreversible complications for 18% of the newborns with PAT, but especially for 10% of the foetuses which will show PAT at birth. HLA markers are very useful to detect the people who are likely to develop an anti-PLA1 immunization for they are PLA1 negative and HLA DR3. Then, it becomes possible to prevent the complications of these immunisations. It is what we tried to do through the diagnosis and the treatment of PAT in 3 foetuses.
D016824:Antigens, Human Platelet; D001787:Blood Group Incompatibility / Q000235:genetics / Q000276:immunology* / Q000517:prevention & control; D001792:Blood Platelets / Q000276:immunology*; D005260:Female; D006680:HLA Antigens / Q000032:analysis / Q000235:genetics; D006684:HLA-DR Antigens / Q000235:genetics; D015803:HLA-DR3 Antigen; D006801:Humans; D007231:Infant, Newborn; D039661:Integrin beta3; D007518:Isoantibodies / Q000032:analysis; D007519:Isoantigens / Q000276:immunology*; D011247:Pregnancy; D012306:Risk; D013921:Thrombocytopenia / Q000235:genetics / Q000276:immunology* / Q000517:prevention & control; D065227:Transfusion Reaction
D016824:Antigens, Human Platelet; D006680:HLA Antigens; D006684:HLA-DR Antigens; D015803:HLA-DR3 Antigen; C061248:ITGB3 protein, human; D039661:Integrin beta3; D007518:Isoantibodies; D007519:Isoantigens
L'immunisation contre l'antigène plaquettaire ZWa (PLA1): groupe à risque, prévention des complications. A propos de 132 cas.